PDS Biotechnology (PDSB) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Tenax Therapeutics (TENX) over the past year, gaining 2.0% versus a loss of 76.2%. Over five years, PDSB leads with a -91.7% price change compared with -99.9% for TENX. PDS Biotechnology is the larger company by market cap ($100.0 million vs $70.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | TENX |
|---|---|---|
| Share price | $1.38 | $1.87 |
| Market cap | $100.01M | $69.98M |
| 1-day change | +35.29% | +0.54% |
| YTD return | +32.47% | -84.74% |
| 1-year return | +2.00% | -76.25% |
| 5-year return | -91.73% | -99.93% |
| EPS (TTM) | $-0.64 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $19.40 |
| 52-week low | $0.195 | $1.31 |
| Distance from 52-week high | -10.97% | -90.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +262.32% | +571.66% |
| Average volume | 23.24M | 5.46M |
| Shares outstanding | 72.47M | 37.42M |
| Employees | 21 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed TENX by 78.2 percentage points over the past year.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
PDSB vs TENX FAQ
Which is bigger, PDS Biotechnology or Tenax Therapeutics?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $69.98M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, PDSB or TENX?
PDSB returned +2.00% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are PDS Biotechnology and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.